Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Septin 9 over expression in MCF7

ABSTRACT: Septin 9 (SEPT9), a member of the septin gene family, is strongly linked to cancer, particularly breast cancer, where genomic amplification occurs in ~11% of cases. SEPT9 is a putative oncogene as it is amplified in the form of double minute chromosomes in murine models of breast cancer, is a fusion partner of mixed lineage leukemia (MLL) gene in leukemia, and it is a known hot spot of retroviral tagging insertion. SEPT9 contributes to cytoskeleton dynamics, thus oncogenic functions have been proposed based on the broad range of cellular functions it partakes. Yet, a clear mechanism by which SEPT9 elicits tumor-promoting functions is lacking. To obtain unbiased insights on molecular signatures of SEPT9 upregulation in breast tumors, we overexpressed several of its isoforms in breast cancer cell lines. Global transcriptomic profiling supports a role of SEPT9 in invasion. Functional studies indicate that SEPT9 upregulation is sufficient to increase degradation of the extracellular matrix, while its downregulation inhibits this process. The degradation pattern is associated with focal adhesions (FA) at the cell periphery. Increased extracellular matrix digestion during epithelial–mesenchymal transition digestion is significantly associated with increased expression of matrix metalloproteinases. In SEPT9 over expressing cells, MMP3 is secreted to the media at FAs. Downregulation of SEPT9 or chemical inhibition of septin filaments assembly impairs recruitment of MMP3 to FAs. Our results indicate that SEPT9 promotes both trafficking and secretion of MMPs near FAs, thus enhancing migration and invasion of breast cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE119449 | GEO | 2018/11/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

ANILLIN REGULATES BREAST CANCER CELL MIGRATION, GROWTH AND METASTASIS BY NON-CANONICAL MECHANISMS INVOLVING CONTROL OF CELL STEMNESS AND DIFFERENTIATION

Project description:Breast cancer metastasis is driven by profound remodeling of the intracellular cytoskeleton enabling efficient cell migration. Anillin is a unique cytoskeletal scaffolding protein that regulates actin filaments, microtubules, septin polymers and Rho GTPases. Anillin is markedly overexpressed in breast cancer and other solid cancer, however its functions in cancer cells remain poorly understood. This study aims at investigating the roles of anillin in regulating breast cancer cell migration, invasion and metastasis. CRISPR/Cas9 technology was used to deplete anillin in highly metastatic MDA-MB-231and BT549 cells and to overexpress it in poorly invasive MCF10AneoT cells. These loss-of-function and gain-of-function studies demonstrated that anillin is necessary and sufficient to accelerate migration, invasion and anchorage-independent growth of breast cancer cells in vitro. Furthermore, loss of anillin markedly attenuated both primary tumor growth and metastasis of breast cancer in vivo. In breast cancer cells, anillin was localized in the nucleus, however anillin knockout affected the cytoplasmic/cortical events such as the organization of actin cytoskeleton and cell-matrix adhesions. This was accompanied by a global transcriptional reprogramming of anillin-depleted breast cancer cells that resulted in suppression of their stemness and induction of the mesenchymal to epithelial trans-differentiation. Such trans-differentiation was manifested by upregulation of basal keratins along with increased expression of E-cadherin and P-cadherin. Knockdown of E-cadherin reversed attenuated migration and invasion of anillin-deficient cells. Our study provides the first evidence that anillin plays causal roles in breast cancer development and metastasis in vitro and in vivo and unravels novel functions of anillin in regulating breast cancer stemness and differentiation.

2020-01-01 | GSE131120 | GEO

Targeting Mmp3 inhibits viability and metastasis of high-metastatic cancer cells

Project description:Cancer metastasis remains an important unsolved problem. Matrix metalloproteinases (MMPs) have been shown to promote cancer cell transformation, migration, invasion, and metastasis through alteration of the extracellular microenvironment, and alter intracellular signaling and genome status. In addition, recent studies have shown intracellular and intranuclear localization, as well as roles of MMPs. In the present study, we examined gene expression signatures of high- and low-metastatic mouse colon cancer cells, and found that Mmp3 was expressed at the highest level in the high-metastatic cells. Profound nuclear localization of Mmps was found in primary explant sites as well as in areas of metastasis in lungs. In addition to the native 50-kDa Mmp3, a short 25-kDa PEX domain and active Mmp3 dimer were found in metastatic cancer cells, indicating novel roles for these forms. Knockdown of Mmp3 attenuated cancer cell viability, migration, and invasion in vitro, along with metastasis in an in vivo transplantation model, as well as cancer cell migration and invasion. These findings suggest that MMPs including intracellular, short, and dimerized forms are involved with malignant progression of cancer, thus they may be suitable as biomarkers and therapeutic targets.

2017-03-30 | GSE97166 | GEO

The invadopodial and cytoskeletal regulator glycine- and cysteine-rich protein 2 induces pro-metastatic matrix metalloproteinase expression in breast cancer cells

Project description:Actin cytoskeleton has multiple functions in cancer cell invasion and metastasis; yet how these functions are coordinated remains unclear. In the cytoplasm, actin is necessary for the formation of specialized membrane protrusions, termed invadopodia, that concentrate and secrete extracellular matrix-degrading enzymes, particularly the matrix metalloproteinases (MMPs), facilitating tumor cell invasion. We recently identified cysteine- and glycine-rich protein 2 (CRP2) as an actin-crosslinking protein whose activity is required for the assembly and elongation of the invadopodium actin backbone. Here, we report that CRP2 is also located in the nucleus of breast cancer cells to induce a complementary pro-metastasis gene expression program mostly related to breast cancer cell invasion and metastasis. We showed in this present study that CRP2 interacts with the transcription factors SRF and GATA3 to regulated the expression of MMP-9 and MMP-13 respectively. Overall, our data indicate that CRP2 act a key mediator of tumor cell invasion.

2023-04-26 | GSE199822 | GEO

Proteomic profiling of the oncogenic septin 9 reveals isoform-specific interactions in breast cancer cells

Project description:Septins are a family of multimeric GTP-binding proteins, which are abnormally expressed in cancer. Septin 9 (SEPT9) is an essential and ubiquitously expressed septin with multiple isoforms, which have differential expression patterns and effects in breast cancer cells. It is unknown, however, if SEPT9 isoforms associate with different molecular networks and functions. Here, we performed a proteomic screen in MCF-7 breast cancer cells to identify the interactome of GFP-SEPT9 isoforms 1, 4 and 5, which vary in the length of their N-terminus. While all three isoforms associated with SEPT2 and SEPT7, the truncated SEPT9_i4 and SEPT9_i5 interacted with septins of the SEPT6 group more promiscuously than SEPT9_i1, which bound predominately SEPT8. Spatial mapping and functional clustering of non-septin partners showed isoform-specific differences in interactions with proteins of distinct subcellular organelles (nuclei, centrosomes, cilia) and functions (signaling, degradation). Notably, the interactome of the full length SEPT9_i1 was more enriched in cytoskeletal regulators, while the truncated SEPT9_i4 and SEPT9_i5 exhibited preferential and isoform-specific interactions with nuclear and signaling factors as well as ubiquitinating enzymes. These data provide evidence for isoform-specific interactions, which arise from truncations in the N-terminal extensions of SEPT9, and point to novel roles in the pathogenesis of breast cancer.

2022-10-13 | PXD012977 | Pride

Expression array of carcinoma cell Mmp14-targeted MMTV-PyMT mammary tumors

Project description:Breast carcinoma cell invasion is thought to depend on the mobilization of the membrane-anchored matrix metalloproteinase, Mmp14/MT1-MMP, to drive the remodeling of extracellular matrix and trigger associated signaling cascades. However, the roles that this proteinase plays during breast tumor progression and invasion in vivo remain undefined. A highly penetrant syngeneic mouse model for luminal B breast cancer driven by the polyoma middle T (PyMT) antigen, in tandem with recently developed Mmp14-floxed mice and MMTV-Cre transgenics that express Cre recombinase throughout the mammary epithelial cell compartment, were used to characterize the impact of conditional Mmp14-targeting on breast carcinoma cell invasion programs in vivo. Transcriptome profiling of intact MMTV-PyMT carcinoma tumors was used to investigate the functional roles of carcinoma cell-derived MT1-MMP in MMTV-PyMT tumor progression and invasion in an unbiased fashion

2018-12-01 | GSE118466 | GEO

High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors

Project description:Clinical and experimental evidence indicates that tumor-associated macrophages (TAMs) promote malignant progression. In breast cancer, TAMs enhance tumor angiogenesis, tumor cell invasion, matrix remodeling, and immune suppression against the tumor. In this study, we examined late-stage mammary tumors from a transgenic mouse model of breast cancer. We used flow cytometry under conditions that minimized gene expression changes to isolate a rigorously defined TAM population previously shown to be associated with invasive carcinoma cells. The gene expression signature of this population was compared with a similar population derived from spleens of non-tumor-bearing mice using high-density oligonucleotide arrays. Using stringent selection criteria, transcript abundance of 460 genes was shown to be differentially regulated between the two populations. Bioinformatic analyses of known functions of these genes indicated that formerly ascribed TAM functions, including suppression of immune activation and matrix remodeling, as well as multiple mediators of tumor angiogenesis, were elevated in TAMs. Further bioinformatic analyses confirmed that a pure and valid TAM gene expression signature in mouse tumors could be used to assess expression of TAMs in human breast cancer. The data derived from these more physiologically relevant autochthonous tumors compared with previous studies in tumor xenografts suggest tactics by which TAMs may regulate tumor angiogenesis and thus provide a basis for exploring other transcriptional mediators of TAM trophic functions within the tumor microenvironment. Tumor-associated macrophages from late-stage mouse mammary tumors compared to splenic macrophages from non-tumor-bearing littermate controls. 4 biological replicates of each population were compared via gene expression arrays.

2010-06-21 | E-GEOD-18404 | biostudies-arrayexpress

SLUG is enhanced by chemotherapeutics and functions to promote invasion and metastasis by directly targeting MMP3 in Cervical Cancer

Project description:SLUG is enhanced by chemotherapeutics and functions to promote invasion and metastasis by directly targeting MMP3 in Cervical Cancer

| PRJNA684312 | ENA

Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling

Project description:An altered consistency of tumor microenvironment facilitates the progression of the tumor towards metastasis. Here we combine data from secretome and proteome analysis using mass spectrometry with microarray data from mesenchymal transformed breast cancer cells (MCF-7-EMT) to elucidate the drivers of epithelial-mesenchymal transition (EMT) and cell invasion. Suppression of connective tissue growth factor (CTGF) reduced invasion in 2D and 3D invasion assays and expression of transforming growth factor-beta-induced protein ig-h3 (TGFBI), Zinc finger E-box-binding homeobox 1 (ZEB1) and lysyl oxidase (LOX), while the adhesion of cell-extracellular matrix (ECM) in mesenchymal transformed breast cancer cells is increased. In contrast, an enhanced expression of CTGF leads to an increased 3D invasion, expression of fibronectin 1 (FN1), secreted protein acidic and cysteine rich (SPARC) and CD44 and a reduced cell ECM adhesion (fig. 1). Gonadotropin-releasing hormone (GnRH) agonist Triptorelin reduces CTGF expression in a Ras homolog family member A (RhoA)-dependent manner. Our results suggest that CTGF drives breast cancer cell invasion in vitro and therefore could be an attractive therapeutic target for drug development to prevent the spread of breast cancer.

2020-10-22 | PXD021539 | Pride

human breast cancer cell line LC-MS/MS

Project description:Long non-coding RNAs (lncRNA) have been identified as key regulators of tumorigenesis and development. We aim to explore the biological functions and molecular mechanisms of lncRNA MIR200CHG in breast cancer. We found that MIR200CHG is highly expressed in breast cancer tissues and is related to the tumor size and histopathological grade. In vitro and in vivo experiments confirmed that MIR200CHG can promote breast cancer proliferation, invasion, and drug resistance. MIR200CHG directly binds to the transcription factor Y-box binding protein-1 (YB-1), and inhibits its ubiquitination and degradation. MIR200CHG regulates YB-1 phosphorylation at serine 102, thereby affecting the expression of genes related to tumor cell proliferation, apoptosis, invasion, and drug resistance. Additionally, MIR200CHG partially affects the expression of miR-200c/141-3p encoded by its intron region. Therefore, MIR200CHG can promote the proliferation, invasion, and drug resistance of breast cancer by interacting with and stabilizing YB-1, and has the potential to become a target for breast cancer treatment.

2022-05-27 | PXD026480 | Pride

Homo sapiens

Project description:Human breast cancer invasion signature

| PRJNA163099 | ENA